The Role of Nueroinflammation in Rosacea

November 1, 2016

Rosacea is one of the most common chronic inflammatory skin diseases, and although it is frequently diagnosed, its pathophysiology is still poorly understood. Continued research has shed some light on the pathophysiology of rosacea and has brought neuroinflammation and neurogenic inflammation to the forefront as an important factor in the development of the disease. The hope is that therapies possibly targeting these pathways could prove effective, offering a beacon of hope for this often challenging to treat skin disease.
Recognized as a complex disease, rosacea can be characterized by a mosaic of symptoms including facial erythema (sometimes burning and painful) and telangiectasias, papules and pustules, as well as facial edema, typically occurring first on the central face around the nose, cheeks, forehead, and chin.
According to the presentation of symptoms, rosacea can be further divided into four subgroups, namely, erythematotelangiectatic rosacea (erythema, flushing, telangiectasias), papulopustular rosacea (erythema, edema, acne-like lesions), phymatous rosacea (rhinophymatous changes), and ocular rosacea (red, itchy, irritated eyes, swollen eyelids).

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Cold Laser Therapy: The Science and Uses for Med Spas
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations